First-ever human clinical trial of a xenoheart intended to support potential registration through the submission of a Biologics License Application to the U.S. FDA
5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call
United Therapeutics Corporation (Nasdaq: UTHR ) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on...
Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in idiopathic pulmonary fibrosis ( IPF ) include efficacy and safety results from ...
UTHR Q1 Deep Dive: Pipeline Advances and Product Launches Dominate Outlook
United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings
United Therapeutics: Q1 Earnings Snapshot
United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2026. Total revenues in the first quarter...
The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag...
Barchart Research What to Expect from UTHR Earnings UTHR Generated May 5, 2026 Current Price $572.20 EPS Estimate $$6.73 Consensus Rating Moderate Buy Average Move 7.25% United Therapeutics Reports Tomorrow...